Search

Displaying results 2291 - 2300 of 10000 in total
  1. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260207] AChR is vital for signal transduction in the neuromuscular junctions (NMJ) by generating muscle end plate potentials to propagate action potential.

  2. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea [L780].

  3. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.

  4. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is designed to allow for lower daily doses and improved patient acceptance and tolerability in comparison to other products in this class of drugs. … ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.

  5. Drug

    Ferric derisomaltose

    go.drugbank.com/drugs/DB15617
    ApprovedInvestigational

    Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. … The latter is an iron carbohydrate oligosaccharide that works to release iron. Ferric derisomaltose was developed by Pharmacosmos Therapeutics ad was granted FDA approval in January 2020.

    Products: Monofer 100 mg/ml solution for injection/infusion in vials, Monofer 100mg/ml solution for injection/infusion in ampoules
  6. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (

  7. Drug

    Bazedoxifene

    go.drugbank.com/drugs/DB06401
    ApprovedInvestigational

    It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … the prevention of postmenopausal osteoporosis in women.

  8. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

  9. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001] … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability.

  10. Drug

    Ethiodized oil

    go.drugbank.com/drugs/DB00965
    ApprovedInvestigational

    Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodo...

    Categories: Compounds used in a research, industrial, or household setting